Member Info for CHELSEA7

Vulpes investment and Board position

In June, Scancell raised gross proceeds of £3,877,965.55 by the issue of 77,559,311 new ordinary shares to Vulpes Life Sciences Fund. Following this investment, Martin Diggle, Co-Founder and Portfolio Manager of Vulpes Investment Management, has been appointed to the Company's Board of Directors as a Non-Executive Director.



Dr Cliff Holloway, Chief Executive Officer, Scancell, commented:



"It has been a busy and productive six months for Scancell. We were pleased to welcome Vulpes as a shareholder in June and their investment not only strengthens our cash position, but provides a ringing endorsement of Scancell's future potential. We look forward to working with Martin Diggle, who will provide valuable insight as a Non-Executive Director.



In addition to expanding our team and establishing a Clinical Advisory Board of world class clinical oncologists, we further advanced our ImmunoBody® and Moditope® pipeline and expanded our intellectual property portfolio. In April, we received UK regulatory approval to initiate the new SCIB1 Phase 2 clinical trial and we look forward to updating the market on the US arm of this trial and patient recruitment in due course."

https://www.investegate.co.uk/scancell-hlds--sclp-/rns/h1-2019-business-update/201907010700109309D/

SCIB1 Phase 2 trial

As reported in April, the Company has received the necessary regulatory and ethical approvals to initiate the UK arm of the SCIB1 clinical trial. Operational activities for clinical centre initiation have been completed and active patient recruitment is anticipated in the coming weeks. The Company continues its dialogue with both Ichor and the FDA with respect to the TriGrid® v2.0 device specific questions and awaits further feedback from the agency with regards to the IND approval which is required to initiate the US arm of the study. The Company will update the market as soon as additional information is available.



Modi-1 manufacturing and preclinical programme

In May, the Company provided an update on progress towards initiating the Modi-1 Phase 1/2 clinical trial, with initiation of Good Manufacturing Practice (GMP) synthesis of the Modi-1 peptide conjugates at the PolyPeptide Group's facilities in The Netherlands. This has been progressed further with formulation work well underway to produce the final product for clinical testing and initiation of the preclinical toxicity testing programme.



Cancer Research UK SCIB2 partnership

Scancell and Cancer Research UK provided an update in May on their clinical development partnership for the development of Scancell's ImmunoBody® vaccine, SCIB2, as a potential treatment for patients with solid tumours. Pre-clinical studies demonstrated that administration of SCIB2 as a liposomal nanoparticle results in potent immune responses and prolonged survival, therefore SCIB2 will be administered using this new nanoparticle formulation in the planned Phase 1/2 clinical trial in patients with solid tumours.



Strengthened team and Clinical Advisory Board established

In January, Scancell strengthened its team by appointing Dr Samantha Paston as Head of Research and Dr Adrian Parry as Head of Manufacturing. Their expertise will be invaluable as we expand our R&D and manufacturing capabilities to further advance our ImmunoBody® and Moditope® pipeline products through clinical development. In May, Scancell appointed six world-leading clinicians to establish its Clinical Advisory Board, chaired by Professor Robert Coleman, to provide strategic guidance around the Moditope® clinical development programme.



Strengthened IP portfolio

During this period, the Company was granted a US patent that provides protection for Modi-1, the first clinical candidate from Scancell's Moditope® platform, a patent that provides protection for the Moditope® platform in Japan, and a European patent relating to FG88, a monoclonal antibody directed to tumour associated glycans.

The movie ""Johnny English"" with Rowan ATKINSON this aftermoon. Inhave spoken a lot of movies, there are my lifeline. How good to see, posters like nomlungu, violidogs hanoirocks sharing their thoughts and hopes today as to Scancell and trials, not just the more recognised horseman for a change.

Time for me to sleep now, and looking forward to whatever it might bring, and delighted it means so much to many others too. Catch yer in the morning guys, onwards, forwards and forever keep on punching...................c7

Crumbs and of course this Vulpes reminder to thir £4m investment to the SCIB1 Combo Trial on jusst 13th June..................

Scancell raises £3.9mln to advance immunotherapy product pipeline
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

Thu, 13 Jun 2019 06:31:00

Nomlungu. I think also many people feel bad they cannotchange the world in the ways we look to, credit goes to those who can do what they can do, not what they can"t. Catch yer tomorrow, goog talkimg this weekend weekend. ATVB

Nomlungu..........Doesn"t bare thinking about does it? I try not to when i can"t chnge things unfortunately, but i repect the many who do ry and suceed in just making it better.

Of course it does crumbs!!!!.................lol.

Well done nomlungu, something I wanted to say was i wondered how hard it must be for the chariries that you have mentioned to raise funds these days when so much of the advertising we see is for cancer donations?

Yes, weathered the heat, just didn"t go out into it !!! I"m afraid it just drains me now, especially the likes of Saturday.

Chester ""will we get news tomorrow""?, well I was hoping we would last Thursday and Friday, but those two buys 500k, 800k suggest we just might do, and the 6.72 paid for both tranches, could well be looked at as bargainbuys in a very short time.

Hope you guys had a good weekend, the weekend for me has gone as quick as the weeks have, to another strong and exciting week. ATB..............

Hanoi, yes I agree with you.

Think you have summed that up British Bulldog, although this market is weird it is our faults we didn"t learn what drives it. Retrospect is a wonderful thing but looking back how many would have actually done anything different. It was those spikes, that made people people feel best not be out of this, and to a lesser degree still fuels hopes for the future. Think it is time to stop blaming yourselves or one another, I have never seen a share like this, but that is only going back 7 years, so I am pretty sure there are others. The only blame i would find hard to let go is that regarding the conduct of the Directors, going back a fairly long way. If there is anything i would like to see is that looked into under a microscope. The only other issue is confirmation bias, but you guys know that now, and hopefully the next ""best thing"" has a better outcome.

Take care, gooodgnight.

No, it has gone to pot, but I will mention at this juncture the awesome work I have seen in the Oncology world, I guess you have seen it too,whether it be in the hospital environment or the voluntary input that is given so freely. I suppose once you have seen that, been on the receiving end of it, nothing in life compares, and that is to the detriment of so much we see in the Health system by and large. I don"t think it is too hard to understand that for those who are doing something that they really want to do, seeing the progress on a daily basis, is something that would drive us all to exceed the standards we set for ourselves in a world largely driven by need and personal gain.

Rattys post a couple of weeks back hit it on the nail for me, when he was saying the progress we have seen in the last few years will be nothing compared to what we will see ahead, and taking into account the level of staffing we are seeing here, along with the qualifications of each additional member of staff, we have every reason to be ever hopeful that we may claim even more of the progress being seen already.

Ruck/Violindog, both relevant points, but I wasn"t really trying to look for excuses for GPs, violindog, you hit the nali on the head just mentioning these 10 minute appointments, I just have a seering anger towards my practice and apart from prescribing my drugs, which they get wrong every month!! I have the least to do with them as humanly possible. That has been achieved simply because with five other consultants involved my oncologist took control of the whole situation and the Hospice dealt with the issues that a doctors surgery would be better known for.

I suppose I wasn"t looking to proportion blame in particular to the GPs surgery, I really don"t know these days whether they even know their role in the Medical food chain, By the time we get an appointment these days the condition has probably improved anyway or we are dead!!! A good point about A1 in healthcare, will do some reading, the death knell of a bedside manner?

Why are Scancell combining SCIB1/2 with checkpoint inhibitors?

Easy to understand................................

Why Scancell is combining SCIB1 and SCIB2 with checkpoint inhibitors #cancervaccinesSCANCELL added,

NYT Health

@NYTHealth
Two scientists won the Nobel Prize in medicine for their work on cancer immunotherapy. Here's a visual explanation for how immunotherapy works: https://nyti.ms/2IuFUtH
1:55 AM - 2 Oct 2018

Interesting article apparantly in todays Daily Telegraph being discussed this morning on Sky News.

Wasn"t aware myself that just 37% of cancers are diagnosed by the NHS after being given an urgent referal from the doctors surgery. I have a problem with the percentages they come up with normally as thereare so many important variables not mentioned but the figures surprised me, and again they weren"t broken down into any particular indications.I find too many spend too much time on the blame game rather than useful time taking responsibility for seeing it through, and the figure annoyed me as our GPs refer us on two basiss, urgent or not.

Again the relevance was hindered by not stating how many of these cancers would have been diagnosed had they have been referred urgently, guess that is a huge area primed to be improved.

I know in my case although I presented with tiredness, coughing and struggling to walk I was never sent for lung x-rays, but that was seven years ago which I trust has been dramatically improved on since.

I have real problems digesting data which is not fully explained as to inclusions and solutions, but I know for all our talk of diagnostics whilst it has improved it has an awful long way to go yet, and it must start in the GPs office, that is after all where it all starts.

A beautiful day on the cards today, enjoy it.

https://www.fiercebiotech.com/research/how-a-long-known-biomarker-backs-biontech-antibody-s-case-for-pancreatic-cancer?mkt_tok=eyJpIjoiT0RJeE9UUmxNemxsTkdNNSIsInQiOiIwQ25zNmZRMW5yZllPa211aFA5dHRUZXV0eUx1YThCXC9oa0FyRDZYR3NHdVJOYWZqK243Q09SMHRFWWd3UFpqYzhRcGVvc0dEWmRXakZhMlVhSlVpdEhiWktTNUhCblRUZzlqNmJkYWdHY0V4dFZ4MEp2SDEyOTNaemk0VXlcL2l0In0%3D&mrkid=36433381

Thanks harley, kind of you to say so, have a great weekend too. Can"t believe where the weeks fly to these days , but I know very little would be flying without so many joining us on this journey. To the good times!! ATB

Same pattern as yesterday that produced the 500k Buy at 16.26. Today there were a few more sells MMs were still taking 220k+ at the close at 6.555 and at 16.27 unsurprisingly we got the 800k buy.

Seemed to me our buyer would have taken whatever amount of shares that were available, and TBH I don"t think they are stopping there., augurs well for Monday and as we said this morning we are looking "primed" for a nice rise, and with additional news IMHO double figures looms large.

Have a great weekend all, thanks for putting up with me this week, I certainly needed your company.

Take care and ATVB

Buys 930k

Sells 660k

Not too many concerns there about the trial not starting by end June, lol??

An 800k BUY at 6.72 from 16.27

The urban myth for a 1 code on a Friday is for an RNS due on Monday. (the first working day after).

Certain codes, as you probably know I have some faith in, simply because time after time they play out. The 1 code is IMHO used on shares which are expecting news anyway simply to ramp and increase trading volumes with the "knowledge" news is indeed coming the following day. With news due by end H1, it would be no surprise to hear confirmation that the trial has started. I have more faith in seeing a buy for aminimum of 500k before the close today personally.

January, well done